MX2022002110A - Optimizacion de formulacion para anticuerpos bisespecificos. - Google Patents
Optimizacion de formulacion para anticuerpos bisespecificos.Info
- Publication number
- MX2022002110A MX2022002110A MX2022002110A MX2022002110A MX2022002110A MX 2022002110 A MX2022002110 A MX 2022002110A MX 2022002110 A MX2022002110 A MX 2022002110A MX 2022002110 A MX2022002110 A MX 2022002110A MX 2022002110 A MX2022002110 A MX 2022002110A
- Authority
- MX
- Mexico
- Prior art keywords
- formulation optimization
- bispecific antibodies
- physico
- systems
- provides methods
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
La presente invención proporciona métodos y sistemas para la optimización de la formulación de anticuerpos biespecíficos. La presente solicitud también proporciona métodos y sistemas para seleccionar moléculas candidatas para la construcción de anticuerpos biespecíficos y la optimización de la formulación de los mismos. Se caracterizan los parámetros fisicoquímicos de un anticuerpo biespecífico. Las estrategias de optimización de la formulación están guiadas por la predicción de los parámetros de interacción. Se proporcionan varias estrategias de optimización de formulación en base a estos parámetros físico-químicos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962889354P | 2019-08-20 | 2019-08-20 | |
| PCT/US2020/047156 WO2021035028A2 (en) | 2019-08-20 | 2020-08-20 | Formulation optimization for bispecific antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002110A true MX2022002110A (es) | 2022-05-18 |
Family
ID=72322561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002110A MX2022002110A (es) | 2019-08-20 | 2020-08-20 | Optimizacion de formulacion para anticuerpos bisespecificos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210054050A1 (es) |
| EP (1) | EP4017877A2 (es) |
| JP (1) | JP2022544818A (es) |
| KR (1) | KR20220047611A (es) |
| CN (1) | CN114787629A (es) |
| AU (1) | AU2020332821A1 (es) |
| BR (1) | BR112022002797A2 (es) |
| CA (1) | CA3151337A1 (es) |
| IL (1) | IL290690A (es) |
| MX (1) | MX2022002110A (es) |
| WO (1) | WO2021035028A2 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106519025B (zh) * | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| CN111402950B (zh) * | 2013-11-29 | 2024-03-19 | 豪夫迈·罗氏有限公司 | 抗体选择装置和方法 |
| WO2016036678A1 (en) * | 2014-09-02 | 2016-03-10 | Medimmune, Llc | Formulations of bispecific antibodies |
-
2020
- 2020-08-20 US US16/998,391 patent/US20210054050A1/en active Pending
- 2020-08-20 CA CA3151337A patent/CA3151337A1/en active Pending
- 2020-08-20 CN CN202080059837.7A patent/CN114787629A/zh active Pending
- 2020-08-20 WO PCT/US2020/047156 patent/WO2021035028A2/en unknown
- 2020-08-20 BR BR112022002797A patent/BR112022002797A2/pt unknown
- 2020-08-20 AU AU2020332821A patent/AU2020332821A1/en active Pending
- 2020-08-20 EP EP20765160.5A patent/EP4017877A2/en active Pending
- 2020-08-20 KR KR1020227008403A patent/KR20220047611A/ko unknown
- 2020-08-20 JP JP2022510829A patent/JP2022544818A/ja active Pending
- 2020-08-20 MX MX2022002110A patent/MX2022002110A/es unknown
-
2022
- 2022-02-17 IL IL290690A patent/IL290690A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114787629A (zh) | 2022-07-22 |
| CA3151337A1 (en) | 2021-02-25 |
| KR20220047611A (ko) | 2022-04-18 |
| WO2021035028A3 (en) | 2021-04-08 |
| US20210054050A1 (en) | 2021-02-25 |
| WO2021035028A2 (en) | 2021-02-25 |
| IL290690A (en) | 2022-04-01 |
| EP4017877A2 (en) | 2022-06-29 |
| JP2022544818A (ja) | 2022-10-21 |
| BR112022002797A2 (pt) | 2022-08-09 |
| AU2020332821A1 (en) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010382A (es) | Anticuerpos biespecificos para pd1 y tim3. | |
| AU2018258045A1 (en) | Chimeric antibody/T-cell receptor constructs and uses thereof | |
| MX2020004129A (es) | Anticuerpos anti-cd38 y metodos de uso. | |
| EA201890302A1 (ru) | Химерные рецепторы антигенов на основе однодоменных антител и способы их применения | |
| EA201592192A1 (ru) | Способ очистки моноклональных антител | |
| EA201791527A1 (ru) | Биспецифические антитела против плазменного калликреина и фактора xii | |
| GT201400045A (es) | Anticuerpo anti-abtcr | |
| EA201990894A1 (ru) | Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения | |
| UY37683A (es) | Anticuerpo monoclonal anti-pd-l1 monoclonal | |
| MX2017004117A (es) | Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171). | |
| EP3941944A4 (en) | B-SPECIFIC CLAUDIN-6 ANTIBODIES | |
| EP3825334A4 (en) | HUMANIZED MONOCLONAL ANTIBODY ANTI-HER3 | |
| EP3917969A4 (en) | NEW BISPECIFIC CD3/CD20 POLYPEPTIDIC COMPLEXES | |
| JOP20210286A1 (ar) | جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr | |
| AU2017428737A8 (en) | Dynamic human heavy chain antibody libraries | |
| EP3997131A4 (en) | CHEMICALLY DRIVEN MONOCLONAL ANTIBODY TARGETING | |
| EP4049684A4 (en) | RI MARKED HUMANIZED ANTIBODIES | |
| AU2017428934A8 (en) | Dynamic human antibody light chain libraries | |
| EP3805390A4 (en) | NAV1.7 MONOCLONAL ANTIBODY | |
| EP4001306A4 (en) | HUMANIZED MONOCLONAL ANTIBODY AGAINST VEGF | |
| MX2022002110A (es) | Optimizacion de formulacion para anticuerpos bisespecificos. | |
| WO2018102594A8 (en) | Methods of treating solid tumors with anti-cd200 antibodies | |
| EP3955925A4 (en) | HUMANIZED ANTI-PD-L1 ANTIBODIES | |
| EP3978015A4 (en) | BISPECIFIC ANTIBODIES | |
| EP3752535A4 (en) | MONOCLONAL ANTIBODY PRODUCTION PROCESS HU14.18K322A |